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The burden of kidney disease: Improving global outcomes.
Chronic kidney disease (CKD) is a worldwide public health
problem. There is an increasing incidence and prevalence of pa-
tients with kidney failure requiring replacement therapy, with
poor outcomes and high cost. There is an even higher prevalence
of patients in earlier stages of CKD, with adverse outcomes such
as kidney failure, cardiovascular disease, and premature death.
Patients at earlier stages of CKD can be detected through labo-
ratory testing and their treatment is effective in slowing the pro-
gression to kidney failure and reducing cardiovascular events.
The science and evidence-based care of these patients are uni-
versal and independent of their geographic location. There is
a clear need to develop a uniform and global public health ap-
proach to the worldwide epidemic of CKD. It is to this end that a
new initiative “Kidney Disease: Improving Global Outcomes”
has been established. Its stated mission is “Improve the care
and outcomes of kidney disease patients worldwide through
promoting coordination, collaboration and integration of ini-
tiatives to develop and implement clinical practice guidelines.”
From an historical perspective, the burden of disease
experienced by human populations has been divided into
three stages: “the age of pestilence and famine,” “the age
of receding pandemics,” and “the age of degenerative and
man-made diseases” [1]. As with most historic changes,
the shift to the current epidemic of chronic noncommu-
nicable diseases is not a simple transition, but rather a
complex and dynamic epidemiologic process with con-
siderable overlap with its preceding stages. Although we
continue to be challenged by new and re-emerging infec-
tious diseases, and while famine and pestilence persist in
much of the world, the reality is that chronic diseases
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now comprise the major epidemic faced in industrial-
ized countries and threatens as an emerging one in many
others [2, 3].
While heart and cerebrovascular diseases and cancer
are the major causes of mortality resulting from chronic
diseases, diseases of the kidney have now also assumed
epidemic proportions as well, and are among the lead-
ing causes of death in the industrialized world. This is in
part due to the number of patients with kidney disease
who progress to kidney failure requiring dialysis or trans-
plantation, whose prognosis is comparable to those with
metastatic cancer. In addition, and at least as important,
it is now evident that in those whose kidney disease may
never progress to dialysis-dependence both the presence
of kidney injury, often signaled by proteinuria, and evi-
dence of decreased kidney function, detected by estimat-
ing the glomerular filtration rate (GFR), are associated
with increased risk of death from heart and cerebrovas-
cular disease due to any cause [4, 5]. As a result, the pres-
ence of kidney disease is now listed as an independent
risk factor for cardiovascular disease in the most recent
report from the Joint National Committee on Prevention,
Detection and Treatment of High Blood pressure (JNC
VII) and in a position statement of the American Heart
Association [6, 7].
Fortunately, concurrent with the increased prevalence
of chronic diseases, the closing decades of the past millen-
nium also witnessed dramatic advances in their therapy.
As a result mortality from heart and cerebrovascular dis-
ease has shown a dramatic decline [8]. By sharp contrast,
that of kidney disease remains unacceptably high and ap-
pears to be increasing in the United States (Fig. 1). While
similar worldwide detailed figures are lacking, wherever
investigated or projected the data are supportive of an
increasing prevalence of deaths attributed to kidney dis-
ease [9–14]. Hence, the clear need to call to action all
health professionals in order to address the worldwide
epidemic of kidney disease.
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Fig. 1. Age-adjusted death rates for the leading causes of death: United
States, 1958–2000. The numbers in circles indicate the rank order of
the disease as a cause of death. 1, diseases of heart; 3, cerebrovascu-
lar diseases; 6, diabetes mellitus; 9, nephritis, nephritic syndrome and
nephrosis; and 13, hypertension with and without renal disease (modi-
fied reproduction from [8]).
CHRONIC KIDNEY DISEASE
Historically, dialysis is the single most important devel-
opment that focused attention on kidney disease, albeit
on its end-stage only. What started in the 1950s as an ex-
ploratory effort to sustain life and relieve the features
of uremia evolved in the 1970s into life-saving replace-
ment therapy for patients whose disease had progressed
to kidney failure. Today, over one million individuals in
the world are alive on maintenance dialysis, a number
that is projected to double in the next decade [13, 14].
Appropriately then, the care of dialysis patients has
been the prime focus of nephrology, particularly after
the widespread availability of maintenance dialysis when
it became evident that mortality of dialyzed patients was
high and their quality of life far from adequate. Initial
efforts to improve care centered on the adequacy of dial-
ysis. This was an important first step in establishing a
minimum dose of delivered dialysis, above which further
increments seem to have little impact on mortality, at least
in the United States where all-cause mortality has ranged
between 21% and 23% per year on dialysis over the past
decade [15, 16]. A principal reason for these results is
the documented heavy burden of co-morbid conditions,
which already exist in patients who are initiated on dialy-
sis. While technical advances and frequent or longer dial-
ysis may further reduce morbidity on dialysis, it would
be simplistic to assume that dialysis would reverse or sig-
nificantly impact the outcomes of existing co-morbidities
such as heart or cerebrovascular disease.
Indeed, it is now evident that the state of health of indi-
viduals with kidney failure who are initiated on dialysis,
and therefore their earlier care, is a major determinant of
survival and well being on maintenance dialysis, and that
persons with kidney disease are more likely to die from
cardiovascular disease than to reach dialysis; hence, the
urgency to focus on early detection and treatment in all
high-risk populations [17–19].
Importantly, and in parallel with the advances in dialy-
sis of the recent past, there has been considerably better
understanding of the progressive course of chronic kid-
ney disease (CKD). This has led to interventions that can
slow the progression and ameliorate the complications
of CKD. Convincing experimental and clinical evidence,
accrued in the past two decades, now shows that (1) the
adverse outcomes of CKD (kidney failure, cardiovascu-
lar disease, and premature death) can be prevented or
delayed; (2) treatment of earlier stages of CKD is effec-
tive in reducing progression to kidney failure and in pre-
venting the systemic complications that develop in the
course of progressive loss of kidney function; and (3)
initiation of treatment of cardiovascular risk factors (ane-
mia, hypertension, dyslipidemia, and altered bone min-
eral metabolism) at earlier stages of CKD can be effective
in reducing this leading cause of mortality and morbidity
of individuals with CKD [7, 17, 18]. Unfortunately, there
is considerable variability in the application of these mea-
sures resulting in lost opportunities to improve outcomes
and making lives better for patients with CKD worldwide
[20].
CLOSING THE GAP: GUIDELINES
The best recent approach to resolve problems of in-
adequate care has been the development of guidelines. It
has now been shown that rigorously developed evidence-
based clinical practice guidelines (CPGs), when imple-
mented, can reduce variability of care, improve patient
outcomes and ameliorate deficiencies in health care de-
livery [21–23]. The practical specificity of well-defined
guideline statements, which facilitates their translation
into clinical practice, differentiates CPGs from other im-
portant evidence-based approaches (meta-analyses and
systematic reviews), which distill and analyze the evi-
dence in the literature but do not make necessary prac-
tical recommendations for clinical practice. There is no
evidence that the passive dissemination of these publi-
cations, even when linked to consensus-derived recom-
mendations, result in changes in clinical practice [24].
On the other hand, the actionable recommendations of
CPGs, when implemented, make them the best tool now
available to close the gap between actual practice and
evidence-based best practice [21, 23]. Indeed, the imple-
mentation of rigorously developed guidelines has been
said to “lead to even greater improvements in patient
care than the introduction of some new technologies”
[24].
The first CPGs in nephrology were developed in
1993 [25]. These initial evidence-based guidelines, which
articulated the minimum dose of hemodialysis and
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recommended how the delivered dose of hemodialysis
should be measured, have been instrumental in achiev-
ing significant improvements in the adequacy dose of
hemodialysis. Building on this initial effort, the National
Kidney Foundation (NKF) launched its Dialysis Out-
comes Quality initiative (DOQI) in 1995. The first four
sets of guidelines developed were hemodialysis adequacy,
peritoneal dialysis adequacy, vascular access, and anemia
that were published in the fall of 1997 [26]. The implemen-
tation of these guidelines, including the development of
federal or insurer-sponsored clinical performance mea-
sures, has been instrumental in changing practice patterns
and their impact on favorably affecting the quality of care
delivered to dialysis patients in the United States has been
documented [27].
During the development of DOQI guidelines it became
evident that the care of patients with CKD should be ini-
tiated well before the need for dialysis and that, in fact,
an even greater opportunity existed to improve outcomes
for individuals with kidney disease starting from the ear-
liest stages of kidney injury and throughout the course of
its progression to kidney failure when dialysis becomes
necessary. This paradigm shift was the basis for a new
and more ambitious phase in which the scope of work
was enlarged to encompass the entire spectrum of kid-
ney disease. To reflect this expansion, the reference to
“dialysis” in DOQI was changed to “disease,” and a new
initiative termed Kidney Disease Outcomes Quality Ini-
tiative (K/DOQI) was launched in 1999.
The first set of new guidelines developed by K/DOQI
on the evaluation, classification and stratification of CKD
was published in February 2002 [28]. For the first time in
the evolution of nephrology, these guidelines provided
a definition of CKD and a classification of the stages
of CKD based on the level of GFR. Subsequent inter-
ventional guidelines, specific to each of these stages, on
dyslipidemia, bone mineral metabolism and disease, and
blood pressure have been published [28]. Others are un-
der development.
Guidelines have also been developed in other coun-
tries. Notable among those are the guidelines developed
by the Canadian Society of Nephrology [29], the Euro-
pean Renal Association-European Dialysis and Trans-
plantation Association (ERA-EDTA) [30], the United
Kingdom Renal Association [31], and the Australian and
New Zealand Society of Nephrology [32]. Others trans-
lated DOQI guidelines, which are now available in over
12 languages, and adopted selected components of them
for local implementation.
A GLOBAL GUIDELINE INITIATIVE
A second paradigm shift in the approach to CKD oc-
curred when it became apparent to those developing
guidelines that there was a need for a more uniform and
global approach to the process. The rationale for a global
initiative is simple and self-evident. Essentially, there is a
recognized and increasing prevalence of kidney disease
worldwide. As such, there is a clear need to develop a pub-
lic health approach to the global epidemic of kidney dis-
ease, coupled with strategic initiatives that can improve
the care of patients with kidney disease worldwide. The
complications and problems encountered by those af-
flicted with kidney disease are universal. The science and
evidence-based care of these complications and problems
are also universal and thus independent of geographic lo-
cation or national borders. It is important to increase the
efficiency of utilizing available expertise and resources in
improving global outcomes of kidney disease. There is
definite room for improving international cooperation in
the development, dissemination, and implementation of
clinical practice guidelines to achieve these goals.
It was on this basis that an initial exploratory and con-
sultative meeting of a group of individuals active in the
field was convened on July 14, 2002, in Copenhagen, Den-
mark during the Annual ERA/EDTA meeting. At the
meeting, enthusiastic support for undertaking a global
initiative was expressed and the decision made that a
Global Coordinating Board would be formed to explore
the issue further.
A GLOBAL COORDINATING BOARD:
REPRESENTATION AND PROCESS
In order to maintain neutrality and independence of
the Global Coordinating Board, no organization or soci-
ety was asked to appoint representative members to the
Board. Rather, nominations were sought from the par-
ticipants in the Copenhagen meeting and other leaders
in the field. Selection was based on clinical expertise and
contributions on an individual basis. The fact that selected
members also held positions in various organizations or
societies, reflecting their own accomplishments and apti-
tudes, were considered a benefit to the initiative rather
than a reason for selection to the Board. Because of lo-
gistics and cost restraints, a decision was made to limit
membership to 30 individuals, with equal representation
from Europe, North and South America, and Africa and
the Far East (Table 1).
The inaugural meeting of the Global Coordinating
Board was held in January 2003 in London. At that meet-
ing, the Board decided to adopt a stepped approach to
the initiative, determined exploratory tasks for Phase I of
the initiative, elected an Executive Committee (Table 2),
assigned management to the National Kidney Founda-
tion, and decided to meet again in December 2003 to
evaluate the progress made and to determine the next
steps.
During the course of 2003, the Executive Committee
held three meetings. The first, which occurred in April
2003 in Rome, defined the objectives of the Global Co-
ordinating Board and constituted Work Groups to ad-
dress each task (Table 3). The second meeting was held in
October 2003 in Amsterdam to review the Work Group
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Table 1. Kidney Disease: Improving Global Outcomes (KDIGO)
Board of Directors
Co-Chairpersons
Garabed Eknoyan, United States
Norbert Lameire, Belgium
Members
Pedro Aljama Garcia, Spain
Thomas Andreoli, United States
Rashad Barsoum, Egypt
Gavin Becker, Australia
Ezequiel Bellorin-Font, Venezuela
Roland Blantz, United States
Emmanuel A. Burdmann, Brazil
Fernando Carrera, Portugal
Jonathan Craig, Australia
Johanna Dwyer, United States
Kai-Uwe Eckardt, Germany
Dennis Fouque, France
William E. Haley, United States
Ronald J. Hogg, United States
Vivekanand Jha, India
Bertram L. Kasiske, United States
Raymond T. Krediet, The Netherlands
Kiyoshi Kurokawa, Japan
Adeera Levin, Canada
Nathan W. Levin, United States
Francesco Locatelli, Italy
Iain C. Macdougall, United Kingdom
Alison MacLeod, United Kingdom
Donna Mapes, United States
Sergio Mezzano, Chile
Louise M. Moist, Canada
Sarala Naicker, South Africa
Jerome Rossert, France
Raymond Vanholder, Belgium
Rowan Walker, Australia
Haiyan Wang, Peoples Republic of China
Christoph Wanner, Germany
Andrzej Wiecek, Poland
Carmine Zoccali, Italy
Table 2. Kidney Disease: Improving Global Outcomes (KDIGO)
Executive Committee
Co-Chairpersons
Garabed Eknoyan, United States
Norbert Lameire, Belgium
Members
Rashad Barsoum, Egypt
Kai-Uwe Eckardt, Germany
Adeera Levin, Canada
Nathan Levin, United States
Francesco Locatelli, Italy
Alison MacLeod, United Kingdom
Raymond Vanholder, Belgium
Rowan Walker, Australia
Haiyan Wang, Peoples Republic of China
reports, develop a structure that would incorporate the
initiative as an independent entity and provide for its
management, and plan proposals for Phase II of the initia-
tive in 2004. At the third meeting, held during the Amer-
ican Society of Nephrology (ASN) meeting in San Diego
in November 2003, the Work Group reports and propos-
als for 2004 were finalized, an agenda for the Global
Coordinating Board meeting was developed, and the
management, structure, name and mission statement for
the initiative were approved.
Table 3. Kidney Disease: Improving Global Outcomes (KDIGO)
Work Groups and Chairpersons
Evidence Rating
Alison MacLeod, United Kingdom
Katrin Uhlig, United States
Chronic Kidney Disease (CKD) Evaluation/Classification
Kai-Uwe Eckardt, Germany
Rowan Walker, Australia
Database/Warehouse
Raymond Vanholder, Belgium
Nathan Levin, United States
Implementation/Regions with Clinical Practice Guidelines (CPGs)
Norbert Lameire, Belgium
Francesco Locatelli, Italy
Implementation/Regions without CPGs
Rashad Barsoum, Egypt
K/DOQI-EBPG Coordination
Raymond Vanholder, Belgium
Garabed Eknoyan, United States
Global Bone and Mineral Metabolism
Sharon Moe, United States
Tilman Drue¨ke, France
At the subsequent meeting of the Global Coordinat-
ing Board in Amsterdam on December 11 and 12, 2003,
the Board reviewed, approved, and accepted the Work
Group reports and plans for 2004, and unanimously ap-
proved the name, mission statement, and structure of the
initiative.
KIDNEY DISEASE: IMPROVING GLOBAL
OUTCOMES
The name under which the initiative is now incorpo-
rated is “Kidney Disease: Improving Global Outcomes”
(KDIGO). Its mission statement is “Improve the care and
outcomes of kidney disease patients worldwide through
promoting coordination, collaboration and integration
of initiatives to develop and implement clinical practice
guidelines.”
The Executive Committee met in London on March
7 and 8, 2004, to put into action plans for the next
2 years. Those plans include (1) the development of a
common methodologic approach, including a uniform
rating system of the strength of the evidence and the rec-
ommendations of guidelines; (2) the adoption of a com-
mon evaluation and classification of CKD to facilitate a
unified nomenclature worldwide; (3) the establishment
of an electronic interactive web-based clearinghouse of
currently available CPGs, including implementation tools
and performance measures to provide direct comparison
of recommended targets in different guidelines together
with the rationale for their differences; (4) the collection
and evaluation of current implementation tools to use
them in facilitating implementation strategies at national
or regional levels; (5) the development of educational
plans and a structure for countries without guidelines to
help the adoption of selected guidelines most suitable
for their regional needs; (6) the evaluation of current
and planned guidelines in different countries with the
intent of integrating the next phase of new or up-dated
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guidelines, on a voluntary basis, into a common process
and their release as global guidelines; (7) the use of con-
troversy conferences to reconcile existing guidelines, es-
tablish what is known, decide what can be done with what
is known, and determine what needs to be known; (8)
integration of the future updating and development of
guidelines under the aegis of KDIGO; (9) the initiation
of the development of one set of new clinical practice
guidelines; and (10) the presentation and dissemination
of results achieved at various national and international
meetings.
THE FUTURE
The ultimate success of these initiatives will depend not
only on the scientific rigor with which they are developed,
but also on their reception by the worldwide nephrology
community. To this end it will need the goodwill and sup-
port of local organizations and thought leaders. Notable
among those is the International Society of Nephrology
(ISN), whose very international nature overlaps with the
global objectives of KDIGO.
Furthermore, the commendable success of the ISN
Commission for the Global Advancement of Nephrology
(COMGAN) provides a unique opportunity for collabo-
rative efforts to achieve the common goal of making lives
better for patients with CKD worldwide. Thanks to the
vision and foresight of the ISN Council and its president,
Jan Weening, steps are already underway to achieve this
end. The challenges ahead are many and the hurdles to
overcome great. However, the future is bright and the
present certainly better than it was only a few years ago.
Ultimately, the goal of KDIGO is to ensure the best
outcomes possible for all individuals with kidney disease.
Through the support and collaboration of all concerned
organizations and individuals, the recognition that there
are common and universal principles of physiology, sci-
ence, and clinical practice should help improve outcomes
of kidney disease worldwide. It is certainly possible to
make the future better than the present.
Reprint requests to Garabed Eknoyan, M.D., Department of Medicine
(523-D), Baylor College of Medicine, One Baylor Plaza, Houston, TX
77030.
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